



(12) **DEMANDE DE BREVET CANADIEN**
CANADIAN PATENT APPLICATION

(13) **A1**

(86) Date de dépôt PCT/PCT Filing Date: 2018/05/29
(87) Date publication PCT/PCT Publication Date: 2018/12/06
(85) Entrée phase nationale/National Entry: 2019/11/15
(86) N° demande PCT/PCT Application No.: US 2018/034866
(87) N° publication PCT/PCT Publication No.: 2018/222583
(30) Priorité/Priority: 2017/05/30 (US62/512,367)

(51) Cl.Int./Int.Cl. *A61K 31/616* (2006.01),
A61K 47/10 (2017.01), *A61K 9/08* (2006.01)

(71) Demandeur/Applicant:
RHOSHAN PHARMACEUTICALS, INC., US

(72) Inventeur/Inventor:
PALEPU, NAGESH R., US

(74) Agent: BERESKIN & PARR LLP/S.E.N.C.R.L.,S.R.L.

(54) Titre : DEPOT EN FLACON D'ACIDE O-ACETYLSALICYLIQUE (ASPIRINE) STABLE, STERILE ET CRISTALLIN
(54) Title: IN-VIAL DEPOSITION OF A STABLE, STERILE AND CRYSTALLINE O-ACETYL SALICYLIC ACID (ASPIRIN)

(57) Abrégé/Abstract:

Improved, stable aspirin formulations for intravenous use are disclosed. Methods of lyophilizing the aspirin from bulk solutions as well as kits containing the lyophilized aspirin and methods of treatment using the same are also disclosed.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(10) International Publication Number
WO 2018/222583 A1

(43) International Publication Date
06 December 2018 (06.12.2018)

WIPO | PCT

(51) International Patent Classification:

A61K 31/60 (2006.01) *A61K 31/616* (2006.01)

(21) International Application Number:

PCT/US2018/034866

(22) International Filing Date:

29 May 2018 (29.05.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/512,367 30 May 2017 (30.05.2017) US

(71) Applicant: **RHO PHARMACEUTICALS, LLC**
[US/US]; 30 Addis Drive, Southampton, Pennsylvania
18966 (US).

(72) Inventor: **PALEPU, Nagesh R.**; 30 Addis Drive,
Southampton, Pennsylvania 18966 (US).

(74) Agent: **MERCANTI, Michael N.**; LUCAS & MERCANTI, LLP, 30 Broad Street, New York, New York 10004 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

WO 2018/222583 A1

(54) Title: IN-VIAL DEPOSITION OF A STABLE, STERILE AND CRYSTALLINE O-ACETYL SALICYLIC ACID (ASPIRIN)

(57) Abstract: Improved, stable aspirin formulations for intravenous use are disclosed. Methods of lyophilizing the aspirin from bulk solutions as well as kits containing the lyophilized aspirin and methods of treatment using the same are also disclosed.

In-vial Deposition of a Stable, Sterile and Crystalline O-Acetyl Salicylic Acid (Aspirin)

Cross-Reference to Related Applications

This application claims the benefit of priority from US Provisional Application Serial No.

5 62/512,367, filed May 30, 2017, the contents of which are incorporated herein by reference.

Field of the Invention

The invention is directed stable forms of injectable aspirin, kits containing the same and methods of treatment using the same.

Background of the Invention

10 Aspirin (o-acetylsalicylic acid, ASA) has been used therapeutically for over 100 years. As a salicylate derivative, it possesses the three properties of non-steroidal anti-inflammatory drugs (NSAIDs): analgesic, anti-pyretic, and anti-inflammatory in treating arthritis, neuralgia and myalgia. In addition to these three properties, Aspirin is also effective in inhibition of platelet aggregation.

15 The principal therapeutic effect of NSAIDs, such as aspirin, is their ability to inhibit prostaglandin production. Aspirin covalently modifies both COX-1 and COX-2, thus resulting in an irreversible inhibition of cyclooxygenase activity, unlike other NSAIDs that bind to COX reversibly. Inhibition of COX-1 leads to inhibition of platelet aggregation but may also cause irritation of gastric lining and kidney function. Inhibition of COX-2 leads to anti-inflammatory, 20 antipyretic and analgesic actions.

Because of the multiple therapeutic activities of aspirin and salicylic acid (SA), which have included the treatment of mild to moderate pain and fever, reduction in risk of chronic diseases such as thrombotic cardiovascular events and, as suggested by emerging evidence, the reduction in risk of colorectal cancer, aspirin has taken many shapes and sizes. Although aspirin was first 25 synthesized in 1897 and sold as a tablet for many decades, over the past three or four decades various dosage forms that include plain tablets, chewable tablets, effervescent tablets, extended-

release tablets, granules and suspensions, fast release/disintegrating tablets, suppositories, powders, creams and lotions have been introduced.

Aspirin is insoluble in acidic pH as the drug predominantly present in the undissociated form, slightly soluble in water (about 0.3%) and the solubility increases significantly at about pH 5.5 and above. The solubility of aspirin is more than 100mg/ml at pH 5.5 and above. Aspirin undergoes hydrolytic degradation at all pH conditions to form salicylic acid. The hydrolysis rate is slowest at about pH 2.5. The hydrolytic degradation of aspirin stays the same in the pH region of 4.5 to 8.5. The degradation half-life is about 6 days, which is not adequate to develop a solution formulation of aspirin. The degradation half-life of aspirin is so short, it is even impossible to lyophilize the concentrated bulk solution as 10% of potency loss can be observed in about 1.3 hours. To lyophilize any drug, the bulk solution should not lose any potency for at least 12 hours under ambient conditions. Even at pH 2.5 where hydrolytic degradation of aspirin is slowest, aspirin degrades at the rate of about 2% per day. Poor solutions stability coupled with low solubility does not permit to develop a commercially viable lyophile. Therefore, the development of a solution or lyophilized form of Aspirin injection in aqueous medium is extremely difficult.

Due to such solubility and stability problems with the injectable dosage form, only oral dosage forms of aspirin are being widely used in treating various indications mentioned earlier. However, orally administered aspirin is not completely absorbed and is slow in the onset of pharmacological action. On the other hand, the effectiveness of intravenously administered aspirin solution was said to be four times as high as that of the orally administered equal amount of acetylsalicylic acid.

It was known that this degradation reaction is pH dependent. A lowering of the pH leads to an increased protonation of released lysine, so that it is not available or only available to a very restricted extent for subsequent reaction with O-acetylsalicylic acid.

All attempts to develop a stable injectable formulation of O-acetylsalicylic acid (ASA) have failed despite extensive development efforts over the past five decades. In our opinion, salts of O-acetylsalicylic with amino acid containing two basic groups are unstable due to disproportionation to the constituent parts of the salts. When the salts are dissolved in water, which may be residual, an ionization equilibrium is set up involving the formation of aspirin and the amine salt former.

The aqueous solubility of aspirin so formed is very low compared to that of the salt and will tend to precipitate thus causing the equilibrium to replace it but at the same time forming more of the amine salt former. In this way, the solution increases in pH and becomes more unstable. Higher 5 pH conditions result in amidolysis of O-acetylsalicylic acid to form amino acid derivative of O-acetylsalicylic acid as well as O-salicylic acid. The presence of such impurities in the injectable formulation of aspirin is not desirable.

Since its discovery of aspirin in 1859, and later worldwide commercialization by Bayer in 1899, 10 O-acetylsalicylic acid (ASA, aspirin; Aspirin ® is registered trademark of Bayer) has been a medical mainstay drug for the treatment of pain, fever, inflammation and inhibition of platelet aggregation in the setting of thrombus (clots).

Aspirin is the only common small molecule drug which also possesses the unique ability to inhibit the aggregation of platelets in the blood, and thus prevent, reduce or eliminate platelet-related 15 clots in blood vessels, tissues and vital organs. Aspirin is only available as an oral tablet or capsule, requiring ingestion by mouth and subsequent absorption in the stomach and GI tract, with onset of inhibition of platelet aggregation occurring from approximately 40 minutes following oral dosing.

When treating platelet-related thrombosis in the setting of heart attack or stroke, minutes count to 20 save lives. Oral tablet aspirin given in the ambulance or ER does not have an immediate effect, relative to rapid-onset of IV infusion clot-busting drugs such as TPA, low-molecular weight heparin and glycoprotein IIb/IIIa inhibitors.

Hundreds of millions of people experience acute (sudden onset) pain, in the settings of headache, 25 migraines, arthritis, musculoskeletal or skin trauma, fractures, dental and surgical wound pain, and from complications of cancer and diabetes. Most analgesic pain medications, including aspirin, are available as oral tablets and take about 30 minutes for initial onset of pain relief. Opioid pain medications are now available as fast-acting and slow-release dosage forms and take about 30 minutes for initial onset of pain relief. However, opioids are widely known to be highly-addictive, and can cause cardio-respiratory distress with standard- or over-dosages.

Thus, the quest continues for a highly-effective, “rapid-onset”, predictable and tolerable agent for inhibition of platelet-related thrombosis, and a non-addicting drug for the treatment of acute pain,

fever, inflammation. Thus, there exist a critical medical need for a parenteral dosage form of aspirin which provides immediate therapeutic action in acute coronary syndrome and other vascular indications.

Summary of the Invention

5 In one aspect of the invention there is provided a liquid aspirin-containing composition having enhanced stability. The composition of the bulk solutions includes aspirin and a cosolvent containing an organic solvent and water. The ratio of the organic solvent to the water is from about 95/5 to 50/50.

In another aspect of the invention there is provided the use of the liquid aspirin-containing 10 compositions as a bulk solution for preparing lyophilized aspirin. A still further aspect of the invention includes methods of preparing lyophilized aspirin. The methods include providing the liquid aspirin containing compositions described herein, lyophilizing the compositions and recovering the resultant lyophilized aspirin. The liquid aspirin containing compositions can contain from about 20 to about 100 mg/ml of aspirin and the cosolvent can include t-butyl alcohol 15 and water. Lyophilized aspirin prepared by the process described herein is also an aspect of the invention. Such lyophilized aspirin having shelf life of at least 2 years under ambient storage conditions.

Still further aspects of the invention include kits for aspirin therapy comprising a first container comprising a therapeutic amount of lyophilized aspirin and a second container comprising water, 20 and a basifying agent and optionally a surfactant such as polysorbate 80. Suitable basifying agents include amino acids or organic bases and inorganic bases or basic salts of alkaline and alkali metals which have a pKa is 8.5 or greater. The amount of the basifying agent is an amount sufficient to provide the solution resulting from combining the contents of the first and second containers with a pH of at least about 5.5 and preferably 6.0 or near physiological pH.

25 Another aspect of the invention is an intravenously-injectable liquid aspirin-containing composition prepared by combining the contents of the first and second containers in the kit described herein. Methods of providing aspirin therapy, comprising: intravenously administering an effective amount of the liquid intravenously-injectable aspirin-containing compositions described herein to a mammal in need thereof.

Brief Description of the Drawings

Figures 1a, 1b, 1c and 1d are X-ray diffractograms of aspirin API, and lyophile made with different concentrations in accordance with the invention and Example 18; and

Figure 2 is an overlay of XRD of tested samples in Example 21.

5

Detailed Description of the Invention

The aqueous solubility of aspirin is about 3mg/ml. This concentration is quite low to administer an adequate dose of aspirin. For example, to administer 100mg about 33.3ml of aspirin solution need to be administered. The volume is large to administer as a bolus injection. The diluted solution must be administered as a rapid infusion injection. For higher doses, higher volumes of aspirin solutions are required. Moreover, solution is acidic; the pH of the solution is about 2.5. Thus, the aspirin solution must be formulated near physiological pH to avoid pain at the injection site and hemolysis. Since aspirin solution is acidic in nature, one way of neutralizing the acidic solution is to treat with an inorganic base. A second approach known in the art is to make basic organic salts of aspirin. Over the past 40 years several scientists have focused on making basic salts of aspirin. The noteworthy or widely popular salt form of aspirin is lysine salt. Extensive research and development activities were carried out on this salt form, but it has been demonstrated to be not as stable as aspirin. Hence, the clinical use of this salt form was restricted to a few hospitals in Germany. Bayer sells this product to a few hospitals with a shelf life of one year. The product they market is a sterile dry powder consisting of 906mg aspirin lysine salt equivalent to 500mg of aspirin and 406mg of L-lysine. In addition, the market presentation included about 50 to 100mg of glycine as stabilizer. We believe that the product is a sterile dry fill mixture of the lysine salt of aspirin and glycine. This sterile dry mixture is constituted with 5ml of water for injection to yield a solution containing 100mg/ml ASA. The 5 ml solution injected in less than 2 minutes. Thromboxane B2 inhibited greater than 95% in 5 minutes of post bolus injection. Inhibition of thromboxane prevents platelet aggregation thus injectable ASA would save life of people suffering from heart attacks.

Our goal was to develop a stable and sterile injectable form of neat aspirin in a vial, which can be reconstituted with a special diluent to yield 100mg/ml ASA solution. We have conducted extensive research on physical mixtures of aspirin with amino acids and co-lyophilization with

amino acids as well as non-aqueous lyophilization. Among the amino acids we tested were arginine, lysine and glycine. We have also tested inorganic basifying agents such as sodium phosphate, dibasic and tribasic, sodium hydroxide, magnesium hydroxide and calcium hydroxide. We have also tested the combinations of amino acids for deprotonation of acetyl salicylic acid 5 with inorganic basifying agents to control the pH of the bulk solution.

In a first aspect of the invention there are provided liquid aspirin-containing compositions having enhanced stability. These compositions are useful as bulk solutions for preparing the lyophilized aspirin. The compositions include aspirin and a cosolvent containing an organic solvent and water. The ratio of the organic solvent to the water being from about 95/5 to 50/50.

10 The organic solvent is preferably an alcohol such as C₂-C₄ alcohols. For example, suitable alcohols include t-butyl alcohol (TBA), n-butanol, ethanol and mixtures thereof. In many aspects of the invention, the alcohol is t-butyl alcohol. The ratio of the alcohol to the water can be from about 60:40 to about 80:20. In some aspects, it is preferably from about 65:35 to about 75:25.

15 The concentration of the aspirin in the composition can be from about 25mg/ml to about 115mg/ml. In some aspects, it is preferably from about 45 mg/ml to about 75 mg/ml or about 50 mg/ml.

20 The liquid aspirin-containing compositions can further include a surfactant, preferably in an amount of from about 0.05 to about 0.5 mg/ml. Suitable surfactants include all pharmaceutically acceptable surfactants known to be useful in lyophilized formulations. In some aspects, the surfactant is polysorbate 80 or Tween 80.

The liquid aspirin-containing compositions can also include a dissolution enhancer, preferably in an amount of from about 2 to about 30 mg/ml, preferably from about 5 to about 20 mg/ml. Suitable dissolution enhancers include without limitation, sucrose or a sugar alcohol, such as mannitol or other pharmaceutically acceptable sugar alcohols known to those of ordinary skill.

25 The liquid aspirin-containing compositions of the invention can also include a buffer, such as TRIS, i.e. tris(hydroxymethyl)aminomethane, glycine or other amino bases with pKa greater than 8.

The liquid aspirin-containing compositions are suitable for use as a bulk solution in the preparation of lyophilized aspirin. The resultant lyophilized compositions are surprisingly stable with minimal amounts of aspirin degradation to salicylic acid. For example, compositions in accordance with the invention demonstrate after 24 hours at ambient temperature degradation amounts of \leq about 2%, preferably \leq about 1%, \leq about 0.5% or \leq about 0.25%.

One preferred liquid aspirin-containing composition in accordance with the present invention is one in which the cosolvent is a mixture of TBA and water, in a ratio of from about 65:35 to about 75:25. The aspirin is present in an amount of from about 45 to about 75 mg/ml, and composition further includes from about 0.05 to about 0.5 mg/ml polysorbate 80 and from about 5 to about 25 mg/ml mannitol.

In alternative aspects of the invention, the bulk liquid aspirin-containing compositions include cosolvent combinations containing TBA/water, n-butanol/water, ethanol/water, PEG-ethanol/water, DMSO/water, DMF/water or PEG/n-butanol/water.

The invention also includes methods of preparing lyophilized aspirin. The methods include providing the liquid aspirin-containing compositions described, lyophilizing the compositions and recovering the resultant lyophilized aspirin. The techniques for lyophilizing the aspirin will be apparent to those of ordinary skill and the based upon the disclosure provided in the examples. The liquid aspirin containing compositions prior to lyophilization can contain from about 20 to about 100 mg/ml of aspirin and the cosolvent includes t-butyl alcohol and water, the ratio of t-butyl alcohol to water being from about 80:20 to about 60:40. In some aspects of the invention, the lyophilized aspirin is crystalline and has a melting point as determined by differential scanning calorimeter or DSC is in the range of 136 °C to 144 °C.

The lyophilized aspirin prepared in accordance with the invention can have a shelf life of at least 2 years under ambient storage conditions and will preferably have less than about 2.0 % total degradation products after 2 years at 25 °C, more preferably, less than about 1.5 % or even lower salicylic acid by weight after 2 years at 25 °C.

The lyophilized aspirin of the invention will also have low levels of residual t-butyl alcohol therein with amounts of less than about 0.5%, preferably from about 500 to about 10,000 ppm or from about 1,000 to about 3,000 ppm in many aspects.

Another feature of the lyophilized aspirin prepared in accordance with the invention is that when it is lyophilized from a bulk solution having a concentration of about 50, 75 or 100 mg/ml. The lyophilized aspirin can have particle size distributions such as:

	Aspirin conc.	D (0.1) μ m	D (0.5) μ m	D (0.9) μ m	D (1.0) μ m
5	50mg/ml	1.8	4.5	9.1	17.6
	75mg/ml	1.8	4.3	8.6	15.6
	100mg/ml	1.4	4.0	8.4	14.8.

In an illustrative example of the transformation of the bulk solution to individual containers housing unit dosages of the lyophilized aspirin it is shown that the bulk solution will include a 10 cosolvent wherein the ratio of

Cosolvent: TBA/Water (ratio): 55/35 to 75/25

Aspirin: 75mg/ml to 45mg/ml

Tween-80: 0.05 to 0.5mg/ml

Mannitol: 5mg/ml to 25mg/ml

15 Fill volume: 4.66 ml to 7.77 ml.

The vials containing the solution are then lyophilized. Fill volumes are calculated based on 350mg of Aspirin per vial. It will be reconstituted to 100mg/ml with 3.5ml of the diluent which is found in the second containers of the kit, for example. This overage will allow practitioners to withdraw 3.25ml of solution and thus 325 mg of aspirin from the vial.

20 The invention also includes a kit for aspirin therapy which contains a first container comprising a therapeutic amount of lyophilized aspirin, for example about 325 mg and a second container comprising water, and a basifying agent for reconstituting the lyophilized aspirin. The second container further comprises a surfactant, preferably in a concentration of from about 0.01 to about 0.4 mg/ml, more preferably about 0.2 mg/ml. The surfactant is polysorbate 80 in many aspects of 25 the invention.

The basifying agent can be selected from suitable amino acids, organic bases and inorganic bases or basic salts of alkaline and alkali metals such as those having a pKa is 8.5 or greater. Some suitable amino acids include arginine, lysine and glycine. An example of a suitable is Tris.

5 Examples of suitable inorganic bases or salt forms include sodium carbonate, sodium bicarbonate and sodium phosphate, dibasic.

The amount of basifying agent included in the second container is an amount sufficient to provide the solution resulting from combining the contents of the first and second containers with a pH of at least about 5.5, preferably about 6.0, more preferably from about 6.0 to about 7.4 or about or near physiological pH.

10 The invention further includes intravenously-injectable liquid aspirin-containing compositions prepared by combining the contents of the first and second containers in the kit. Such compositions will preferably have a tonicity of from about 270 to about 1300 mOsm/kg.

15 In accordance with the foregoing one intravenously injectable liquid aspirin containing composition will include from about 20 to about 140 mg/ml, preferably about 100 mg/ml of aspirin, a sugar alcohol, preferably mannitol and a surfactant with less than about 0.1% TBA therein.

20 The invention also includes methods of providing aspirin therapy. The methods include intravenously administering an effective amount of the liquid intravenously-injectable aspirin-containing compositions described herein to a mammal such as a human in need thereof. In practice, the methods also include combining the contents of the two containers provided preferably in the form of a kit which optionally includes directions for use of the aspirin composition, and intravenously administering the resultant composition. The amount of aspirin administered intravenously can be from about 80 to about 1200 mg, and can preferably be from about 300 to about 1000 mg. In some aspects of the invention, container in which the lyophilized aspirin is placed will contain an amount sufficient to deliver 325 mg of aspirin in a 3.25 ml dose.

25 The aspirin concentration of the composition intravenously administered can be from about 20 to about 100 mg/ml, or in higher concentrations if desired, and the volume of the intravenously-injectable aspirin-containing composition administered is from about 1ml to about 10 ml. In some preferred aspects, the concentration of the aspirin administered will be about 100 mg/ml.

The intravenously-injectable aspirin-containing composition can be intravenously administered over a period of about 120 seconds or less and preferably over a period of about 90 seconds or less. Such methods of administration are especially well suited for the treatment of platelet-related thrombosis in the setting of a heart attack or stroke. The compositions of the invention 5 can therefore be advantageously included with ambulances and crash carts used in hospitals and emergency room applications to provide immediate therapeutic action for acute coronary conditions.

Further Methods of Treatment

The reconstituted aspirin compositions described herein can be used in any aspirin therapy known 10 to those of ordinary skill. For example, and without limitation, the aspirin therapy can be used to treat at least one the following:

- a) vascular indications including ischemic stroke, TIA, acute MI, prevention of recurrent MI, unstable angina pectoris, chronic stable angina pectoris,
- b) reducing the combined risk of death and nonfatal stroke or transient ischemia of the brain due to fibrin platelet emboli;
- c) reducing the risk of vascular mortality in patients with a suspected acute MI;
- d) reducing the combined risk of death and nonfatal MI in patients with a previous MI or unstable angina pectoris, and (4) reduce the combined risk of MI and sudden death in patients with chronic angina pectoris;

20

- b) Revascularization Procedures (Coronary Artery Bypass Graft (CABG), Percutaneous Transluminal Coronary Angioplasty (PTCA), and Carotid Endarterectomy): Aspirin is indicated in patients who have undergone revascularization procedures (i.e., CABG, PTCA or carotid endarterectomy) when there is a preexisting condition for which aspirin is already indicated;

25

- c) Rheumatologic Disease Indications (Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis, Spondyloarthropathies, Osteoarthritis, and the Arthritis and Pleurisy of Systemic Lupus Erythematosus (SLE)): Aspirin is indicated for the relief of

symptoms of rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, spondyloarthropathies, and arthritis and pleurisy associate with SLE. and

d) Kawasaki's disease or mucocutaneous lymph node syndrome.

5

In the case wherein the indication is Kawasaki's disease, the amount of aspirin administered is from about 80 to about 100 mg per kg per day or from about 3 to about 5 mg per kg per day. Other dosage regimens will be apparent to those of ordinary skill without undue experimentation.

10 **Examples:**

Example 1

We first evaluated the chemical stability of molar equivalents of physical blends of aspirin with lysine and aspirin with glycine. In the first experiment 5g of aspirin and 4.06 g of l-lysine were mixed thoroughly in a mortar and pestle and the blend was passed through a 100-mesh screen. A 15 physical blend (906mg equivalent to 500mg aspirin) was weighed into several 5 mL, type I, flint glass vials, stoppered and capped. These vials were placed at 40 °C and 25 °C analyzed for aspirin and salicylic acid (major degradant of aspirin) up to three months storage.

Similarly, a physical mixture consisting of 5g of aspirin and 2.08g of glycine was prepared and the stability of this physical mixture was similarly evaluated. The stability data are presented in 20 Table 1.

Table 1: Solid state stability of physical blends of aspirin with lysine and glycine at 40°C

Formulation	Storage time	Aspirin (mg/vial)	% of target	Area % SA
Aspirin-Lysine Physical mixture	Initial	526.4	105.3	2.20
	1M	482.6	96.5	2.05
	2M	471.6	94.3	8.60
	3M/25°C	495.5	94.1	5.23
	1year/25°C	499.9	94.9	7.52
Aspirin-Glycine Physical mixture	Initial	485.2	97.0	0.14
	1M	490.0	97.6	0.03
	2M	489.4	97.9	0.14
	3M	501.9	102.7	0.11
	1year/25°C	555.6	114.5	0.53

The stability data suggested that aspirin-lysine physical blend is not quite stable as we observed a potency loss of about 6% with a corresponding increase in salicylic acid which is the primary degradant of aspirin. The stability assessment will be based on the formation of salicylic acid 5 during storage. The amount of salicylic acid should not exceed 3% during the shelf life. However, three months' analysis of aspirin-lysine physical blend stored at 25°C showed formation of about 5% of salicylic acid and about 7.5% at the end of one year storage indicating that the physical blend is not stable.

The physical blend of aspirin-glycine was, however, showed no degradation after a 3-months' 10 storage at 40°C and one year at 25°C suggesting that it is feasible to develop a robust formulation of an aspirin-glycine physical blend (1:1 on a molar basis) if one can aseptically blend the sterile aspirin powder with sterile glycine and fill into vials aseptically. This is a labor-intensive and expensive process and may be difficult to source the sterile grade of aspirin as well as glycine. In principle the physical blend can be filled non-aseptically into vials and the finished product can be 15 sterilized by gamma radiation. However, we found in the literature (30) that three degradants were seen by gamma-irradiation of aspirin. Therefore, gamma-irradiation would not be a viable option to sterilize the physical blend of aspirin-glycine.

Example 2

We have also tried to lyophilize aspirin with lysine. Equimolar amounts of aspirin and lysine were 20 dissolved in water to a targeted aspirin concentration in the solution of 50mg/ml. After stirring for 15 minutes we observed that part of the ASA was not dissolved. The pH of the solution was 4.5. We added an additional amount of lysine to raise the pH of the bulk solution to 6.5. When all the drug was dissolved, a clear solution was formed. The solution was then filtered and 10ml aliquots of the solution were placed into 20cc vials and lyophilized to attain a dose of 500mg ASA per 25 vial. The product, however, was not lyophilized properly. The lyophilized cake collapsed. HPLC analysis suggested that about 40% of ASA had degraded during the lyophilization process. Based on these data and extensive laboratory studies conducted to produce a stable lyophilized formulation using water and organic bases to dissolve ASA, we have concluded that 30 lyophilization of ASA with lysine or other organic bases using water as dissolution medium is not feasible.

Example 3

In a subsequent set of experiments, we have explored inorganic bases/buffers in water to dissolve ASA, we made a 20mg/ml slurry of ASA where the solubilization of ASA took place by raising the pH to 6.5 using three different techniques:

- 5 3A. Using Sodium hydroxide pellets
- 3B. Using disodium hydrogen phosphate
- 3C. Using sodium hydroxide powder to rise pH to 5.0 and then disodium hydrogen phosphate to adjust the pH to 6.5. This procedure allowed us to control pH better than 3A

All three solutions were filtered and 5ml each placed in a Type I flint vials and lyophilized. Upon
10 completion of lyophilization, vials were observed for physical appearance. The lyophilized cakes in all vials were shrunken and collapsed. HPLC analyses suggested that more than 10% of ASA had converted to its major degradant, salicylic acid. Since lyophilization of the ASA-lysine solution was carried out at about -30 °C, all water was removed by sublimation at this low temperature. It is not known whether degradation took place during the lyophilization or during
15 the preparation of the bulk solution or combination of both. Therefore, we have investigated the bulk solution stability of example 3C at 25 °C. The stability data are presented in the Table-2 below

Table 2: Bulk solution stability of Example 3C at 25°C

Assay Time	Amount of Aspirin (mg)	% Initial	Area% of Salicylic Acid
Initial	98.2	100	3.1
4hours	90.0	90.9	9.1
8hours	89.0	89.9	9.9
24hours	82.5	83.3	19.1

20 As shown in the above table, about 3% of salicylic acid was initially formed when all ASA dissolved. Salicylic acid levels rose to about 9% within 4 hours. From these experiments, it was clear that aqueous lyophilization of ASA is not feasible. For a robust manufacturing process, we should not observe any degradation of ASA in the bulk solution for lyophilization for at least 24 hours.

Example 4

Since aqueous lyophilization of ASA in the weakly acidic (pH 4-6.5) and weakly basic (above pH 7.0) range is not possible, we have explored the use of non-aqueous solvents to improve the bulk solution stability of ASA. Aspirin is quite soluble in ethanol (80 mg/ml), dimethyl sulfoxide, 5 DMSO, (41mg/ml) and dimethyl formamide, DMF, (30mg/ml). Pure ethanol cannot be used for lyophilization as it does not freeze and is very difficult to remove during the lyophilization process without damaging the final finished product. Both DMSO and DMF are caustic solvents which damages polymeric materials such as gaskets and other housing material in the chamber of lyophilizer. Hence these two solvents have been rarely used in the lyophilization process. There 10 are a few products which have used ethanol as a co-solvent with water in the lyophilization process, however, ethanol levels are restricted to 10 to 15% by volume.

Example 5

To overcome the issues around lyophilization with the aforementioned solvents, we have investigated the use of t-butyl alcohol (TBA). TBA is, however, not a powerful aprotic solvent 15 like ethanol, DMSO or DMF. In a first step, we measured the saturation solubility of ASA in pure t-butyl alcohol and binary solvents containing different ratios of water and TBA. It was surprisingly found that aspirin is highly soluble in TBA, much higher (about 1.5 to 4-fold) than the reported solubility of aspirin in ethanol, DMSO and DMF. We also measured the solubility of Aspirin in other C3-C4 aliphatic alcohols such as n-butanol, n-propanol and isopropanol. Also 20 measured solubility of aspirin in other aprotic solvents such as propylene glycol and polyethylene glycol 400. The data summarized in Table-3

The solubility of aspirin even in a TBA/water (60/40) mixture is higher than the solubility of aspirin in pure ethanol. This is really an important invention or finding as incorporation of water in the solvent mixture allows for the presence of water soluble excipients such as bulking agents 25 in the bulk solution for lyophilization. For example, if we want to co-lyophilize ASA with any basic amino acid or with some inorganic basifying agents or bulking agents such as mannitol or sucrose, we need water in the solvent system to dissolve these excipients; as they are not soluble in TBA alone. The solubility data of ASA in different solvents and TBA/water system are presented in Table 3.

Table 3: Solubility of ASA in organic solvents and in various ratios of TBA-Water systems

Solvent system	~Solubility of Aspirin (mg/ml)
Propylene glycol	155
Polyethylene glycol 400	150
n-propanol	130
isopropanol	140
n-butanol	100
TBA	150
TBA : Water (80:20)	120
TBA : Water (60:40)	105
TBA : Water (40:60)	50
TBA : Water (30:70)	38
TBA : Water (25:75)	18
TBA : Water (20:80)	9

As shown in the table above, the solubility of ASA reached its targeted concentration of 100mg/mL in 80%/20% TBA/water (v/v) system. Please note that all references to a TBA/water ratio in this document is based on (v/v) basis. Generally, the solubility of drugs that are poorly soluble in water, decreases in the mixed solvent systems with increasing water percent. We have observed the same behavior in TBA/water system.

Procedure for solubility determination:

A small aliquot of API was added to the vehicle and left on the magnetic stirrer, stirring at 500 RPM and heating if needed until dissolved. Once clear solution was obtained, we added another small portion of drug to facilitate further dissolution of the drug. This process was repeated to obtain the saturation solubility. The solutions were filtered, transferred to vials, stoppered and crimped and used for physical observation and HPLC analysis.

15

Example 6

As mentioned earlier, the primary criterion for lyophilization is the stability of ASA in the bulk solution. For a robust lyophilization process, the drug should not degrade in the bulk solution for lyophilization for at least 24 hours. We examined the stability of ASA for 24 hours in 80/20, 70/30 and 60/40 TBA/water solutions. No appreciable degradation was observed in all tested systems over a 24-hour storage at ambient storage conditions. The stability data presented in Table 4 below

Table -4: Bulk solution stability of ASA in various compositions of TBA-water system

Composition of Bulk Solution	ASA concentration	Time Period	Content (mg/mL)	S.A Content
TBA:WFI(80:20)	50mg/mL	0Hrs	52.0	0.11
		4Hrs	49.6	0.13
		8Hrs	48.7	0.14
		24Hrs	48.4	0.34
TBA:WFI(70:30)	50mg/mL	0Hrs	46.4	0.11
		4Hrs	53.3	0.16
		8Hrs	51.4	0.18
		24Hrs	52.4	0.48
TBA:WFI (60:40)	50mg/mL	0Hrs	47.9	0.13
		4Hrs	54.2	0.18
		8Hrs	54.0	0.23
		24Hrs	53.4	0.61
TBA:WFI(75:25)	100mg/mL	0Hrs	100.3	0.26
		4Hrs	100.3	0.39
		8Hrs	99.9	0.53
		24Hrs	99.5	0.64
		48Hrs	98.7	0.64
TBA:WFI (65:35)	100mg/mL	0Hrs	101.6	0.25
		4Hrs	100.1	0.39
		8Hrs	100.0	0.60
		24Hrs	99.4	0.75
		48Hrs	99.4	0.78
TBA:WFI (60:40)	100mg/mL	0Hrs	101.0	0.24
		4Hrs	99.6	0.44
		8Hrs	100.7	0.62
		24Hrs	100.6	0.80
		48Hrs	99.9	0.89

There are no changes in the physical appearance of bulk solutions during the storage time.

Solutions are clear and colorless.

Based on the generated information on the solubility and stability of ASA in TBA/water systems, we have undertaken the following lyophilization studies. A 20mg/ml batch of aspirin in 80% TBA/20 water was prepared where the apparent pH of the bulk solution was 2.9. The pH of the solution was raised to 6.5 using 1N sodium hydroxide. Phase separation was observed, probably

due to salting out of inorganic base from TBA/Water system. In the next trial, we first raised the pH of the solution to 5.0 using 1N sodium hydroxide, and then sodium phosphate, dibasic to raise the pH to 6.5. Sodium phosphate, dibasic was used for a better control of pH. Since we still observed phase separation it appears that inorganic bases or buffers may not be compatible with 5 a80%TBA/20%water system. We may require more water, for example, 70%TBA/30%water in the system to dissolve the alkalinizing agents.

Example 8

Subsequently, we have investigated the possibility of incorporating an organic amino acid base such as arginine, lysine or glycine with ASA in the lyophilization process. Since both lysine and 10 arginine are sparingly soluble in an 80/20 TBA/water mixture we used 70/30 TBA/water as the solvent for lyophilization; the solubility of arginine in this solvent system is about 10mg/ml, in lysine it is 2mg/ml, glycine it is 3mg/ml and in Tris it is 5mg/ml. Inorganic buffers such as sodium phosphate, dibasic, are not soluble in this solvent system. However, these solubility values are not adequate to neutralize aspirin. Aqueous titration studies have indicated that about 15 90mg of arginine is needed to neutralize 100mg of ASA to make a 20mg/ml aspirin solution at pH about 6.0. Therefore, among the amino acid buffers arginine and Tris were only amino acid buffer that has reasonable solubility in 70/30 TBA/water system. Hence incorporation of an adequate concentration of amino acid, other than arginine or Tris or inorganic base, to neutralize ASA in TBA/water solvent for co-lyophilization of ASA is not feasible. Even this amount of 20 arginine is not sufficient to completely neutralize ASA. Also, we have measured the solubility of the neat free bases of amino acids in above study without ASA. The solubility of arginine may be different when ASA neutralizes arginine free base in the 70% TBA/30% water system.

To test our hypothesis, 2g of ASA was added to 80ml of 70/30 TBA/water solvent system. Arginine was slowly added to the clear solution to neutralize aspirin. About 1.8g arginine was 25 added for complete dissolution. The batch volume was made up to 100 ml with addition of 70/30 TBA/water. Measured arginine solubility is 18mg/ml which is significantly higher than the solubility of arginine free base alone (~10mg/ml) The apparent pH of the bulk solution was 6.28.

5ml aliquots were placed in flint vials and lyophilized. Upon completion of lyophilization, the contents of the vial were reconstituted with 5ml of Water for Injection. All the drug was

dissolved, but a slight haziness was seen. The reconstituted solution pH was 4.71. The bulk solution for lyophilization had 70% TBA, therefore, the pH value of 6.24 was an apparent pH in 70/30 TBA/water system. The reconstituted solution was essentially free of TBA and what was observed was the true intrinsic pH of the 20mg/ml aspirin solution, which suggest that all ASA was not completely neutralized. A pH of above 6 in the aqueous solution denotes complete neutralization of aspirin.

Example 9

In the next trial, we investigated incorporation of sodium hydroxide to facilitate complete neutralization. To 80 ml of 70/30 TBA/water solvent system and 2g of aspirin slurry 100 mg sodium hydroxide was added. Arginine was, then, slowly added to the slurry to neutralize aspirin. About 1.6g arginine was added for complete dissolution. The batch volume was made up to 100 ml with addition of 70/30 TBA/water. The apparent pH of the bulk solution was 6.49. 5ml aliquots placed in flint vials and lyophilized. Upon completion of lyophilization, the content of vial was reconstituted with 5ml of Water for Injection. All drug was dissolved, but slight haziness was observed. The reconstituted solution pH was 4.8. Even incorporation free base like sodium hydroxide did not neutralize the aspirin in the 70%TBA/30%water system.

Based on the above studies, it was evident that larger amount of base is needed to neutralize ASA in the preferred solvent system. To incorporate more base in the bulk solution, we explored use of 60/40 TBA/water system as solvent for lyophilization. To 80 ml of 60/40 TBA/water solvent system and 2g of ASA solution, 400 mg sodium hydroxide was added. The batch volume was made up to 100 ml with addition of 60/40 TBA/water. The apparent pH of the bulk solution was 6.31. 5ml aliquots were placed in flint vials and lyophilized. Upon completion of the lyophilization, the contents of each vial were reconstituted with 5ml of Water for Injection. Almost all the drug was dissolved, but a slight haziness was seen. The reconstituted solution pH was 4.41. Even incorporation of a higher amount of a base like sodium hydroxide did not solubilize the aspirin in the bulk solution for lyophilization. The appearance of the lyophilized cake was not good; the cake was shrunken with some melt back. We reconstituted the lyophile with 5ml of buffer solution containing different concentrations of disodium phosphate. The titration data is presented in Table 5.

Table 5: Reconstitution of lyophile with different concentrations of Na₂HPO₄

Concentration of Na ₂ HPO ₄	pH
0	4.41
1 mg/ml	4.46
1.25 mg/ml	4.54
1.5 mg/ml	4.62
1.75 mg/ml	4.78
2.0 mg/ml	4.92
3.5 mg/ml	5.21

The titration data suggested that the solvent system for lyophilization should hold at least 350mg of sodium phosphate, dibasic, in addition to 400mg sodium hydroxide to raise the pH of 5 reconstituted solution to above 5.

Example 10

In all above examples, the reconstituted solutions were hazy. It was not clear whether the haziness was due to low pH or due to the intrinsic nature of the lyophile. We made a batch cited in example 8 and reconstituted to different concentrations using sodium phosphate, dibasic with 10 and without neutral and amphiphilic surfactants. The pH of the reconstituted solution is 4.71. The reconstitution of lyophile to different concentrations in different media are presented in Table 6.

Table 6: Physical appearance of Aspirin lyophile at different concentrations in different media

Reconstituted Medium	Diluents volume	Conc. of drug	Appearance	pH
2.0 mg/mL Disodium hydrogen phosphate anhydrous in WFI	5.0 mL	20.0 mg/mL	Slight haziness	6.49
	6.7 mL	15.0 mg/mL	Slight haziness	6.72
	8.0 mL	12.5 mg/mL	Slight haziness	6.84
	10.0 mL	10.0 mg/mL	Slight haziness	7.03
2mg/mL of Disodium hydrogen phosphate in 0.05% of Tween80 solution	5.0 mL	20.0 mg/mL	Slight haziness	6.39
	6.7 mL	15.0 mg/mL	Slight haziness	6.70
	8.0 mL	12.5 mg/mL	Slight haziness	6.82
	10.0 mL	10.0 mg/mL	Slight haziness	6.94
2mg/mL of Disodium hydrogen phosphate and 1mg/mL TPGS in water for injection	5.0 mL	20.0 mg/mL	Slight haziness	6.33
	6.7 mL	15.0 mg/mL	Slight haziness	6.69
	8.0 mL	12.5 mg/mL	Slight haziness	6.89
	10.0 mL	10.0 mg/mL	Slight haziness	6.96

All reconstituted solutions showed haziness at all concentrations despite achieving the target pH. We speculated that the haziness might possible due to degradation of aspirin in the bulk solution. Hence, we tested the lyophile for potency and potential degradation product. HPLC analysis showed a potency loss of 17.4%. Salicylic acid formation was 7.2 area%. There other unknown degradants were observed which are less than 0.2 area%. Possibly the haziness was due to these unknown degradants. Significant potency loss during the lyophilization was a major concern for the development of a robust and stable lyophilized formulation of ASA with a base neutralizer. To confirm whether the instability was found only this batch or other batches, we have analyzed two batches prepared using 70/30 TBA/water as solvent for lyophilization that were stored under ambient conditions over a month. The stability data are presented in Table 7.

Table 7: Stability of Aspirin lyophiles stored under ambient conditions for 1 month

Composition	Potency	% of degradants				% of Total
		RRT 0.45	RRT 0.51	Salicylic acid	RRT 2.73	
Aspirin -100mg Arginine- 80mg NaOH -2.5mg	54.0	0.91	0.78	39.6	0.76	42.0
Aspirin -100mg Arginine- 80mg NaOH -3.75mg	52.5	0.63	0.77	35.5	0.64	37.6

As shown in the table above, about 50% potency loss was observed in over a month's storage under ambient conditions. Three additional degradation products besides salicylic acid were observed; salicylic acid being the major degradant. Our studies suggested that lyophilization of ASA via partial or complete neutralization using an amino acid or an inorganic base or combination of both in a solvent system containing TBA/water is not feasible. Moreover, the lyophiles obtained in the above examples are amorphous in nature, and ASA is not stable in its amorphous form.

20

Example 11

Extensive formulation screening studies were conducted to co-lyophilize ASA with different basifying agents, preferably arginine, lysine and Tris, to produce a lyophile that can be upon

reconstitution with water result in a clear solution around pH6 or above. These studies have indicated that the bulk solution stability was not adequate to scale up the process. Moreover, the solid state stability of these lyophiles were too poor to produce a commercially viable product. Furthermore, we could not incorporate an adequate amount of water soluble basifying agent in the 5 bulk solution, which was 80%TBA/20% water, for lyophilization to bring the final pH of the reconstituted solution lyophilized product to a value of 6 or above.

The only other approach we have left with is lyophilizing ASA “as is” in (free acid form) TBA/water solvent system without adding any basifying agent. This approach will produce a lyophile of pure ASA which is acidic in nature and not soluble in water upon reconstitution. 10 Therefore, the lyophile would require a special diluent for reconstitution which can neutralize the acidic ASA and produce a clear solution where the final pH of the solution is 6 or greater.

Based on these considerations, we have produced two lyophilized batches by dissolving aspirin to a concentration of 20mg/ml in 80% TBA/20%water (v/v) solvent system. 5ml of aliquots were transferred into 10cc vials and lyophilized. The batch size was 90ml for the first batch (Example 15 11A, manufactured on 31-May-2013) and 220ml for the second batch (Example-11B, manufactured on 3-Sep-2013). Solid state stability for these two batches were evaluated at different temperatures and the stability data are summarized in the Table 8.

Table 8: Solid State Stability of batches -11 A&B

Batch ID	Storage Temp.	Storage time	% of Initial	Salicylic acid	Area% of total DP*
Example-11A	40°C	Initial	100	0.69	0.79
		1M	99.5	0.78	0.91
		2M	99.7	1.72	1.82
		3M	99.4	0.92	0.99
		6M	99.3	0.68	0.73
		Initial	100.0	0.10	0.10
Example -11B	40°C	1M	99.4	0.32	0.37
		2M	100.1	0.48	0.53
		3M	95.0	0.55	0.60
		6M	101.6	0.89	1.00
		3M	99.8	0.39	0.43
	30°C	6M	97.1	0.46	0.50
		9M	96.0	0.68	0.71

25°C	12M	96.3	0.66	0.72
	3M	99.7	0.31	0.35
	6M	99.4	0.36	0.40
	9M	99.0	0.50	0.53
	12M	99.6	0.55	0.58
	18M	98.8	0.67	0.72

*DP: Degradation products, sum of known and unknown degradants

As shown in the table above, we have produced extremely stable product as insignificant potency loss was observed at 40°C, over a 6-month storage. It is unusual for a lyophilized product to show 5 no potency loss under this accelerated condition.

Since the lyophilization of neat ASA produced a stable lyophile, we have optimized the lyophilization cycle and the final lyophilization conditions are presented in Table 9.

10 **Table 9: General lyophilization conditions followed to lyophilize ASA in TBA/Water system**

Steps	Condition	Shelf Temp, °C	Time, Min	Pressure, m Torr
Loading		RT	-	-
Freezing				-
		-40°C	4-8hours	-
Primary Drying		-40°C to -10°C		200
				200
		-10°C to 0°C		200
Secondary drying		0°C	240 18-22 hours	200
		0°C to 25°C	180	150
		25°C	84010-12 hours	150
N ₂ Back fill	-	25°C	-	~11 Psia
Stopper the vials, seal them with aluminum caps				

Example 12

After optimization of lyophilization cycle, two lyophilized batches were manufactured by dissolving aspirin to a concentration of 20mg/ml in 80% TBA/20%water (v/v) solvent system. 15 Aliquots of 5 mL were transferred into 10ccvials and lyophilized. The batch size was 1,000ml for the first batch (Example 12A) and 900ml for the second batch (Example-12B). Solid state stability of these two batches were evaluated at different temperatures and the stability data are summarized in Table 10. We have conducted stability studies up to 6 months at 40°C, and 9 months at 30°C and 25°C for the batch -12A. For the batch -12B, we have conducted stability

studies up to 6 months at 40°C, and up to 12 months at 30°C and up to two years at 25°C. Both batches exhibited outstanding stability; only 1.4% potency loss was seen after 24 months' storage at 25°C while the salicylic acid content increased from 0.1% to 0.48% for the batch -12B. There are no other degradant peaks observed that were above the limit of quantification of the method.

5 We have not observed any degradation even under accelerated conditions and no shrinkage of cake even after storing at 40°C/6M. This was quite unusual and unexpected for a lyophilized product to exhibit extraordinary stability at 40°C/6M storage condition. The data clearly demonstrated that the lyophilization process where ASA present predominantly in the unionized form surprisingly and unexpectedly produced a very stable ASA product. The stability data are

10 presented in the Table 10.

Table 10: Solid State Stability of ASA batches -12 A&B

Batch ID	Storage/Time		Mg/vial	% of Initial	Salicylic Acid
Example 12A	Initial		99.4	100.0	0.09
	40°C 75% RH	2M	96.1	96.7	0.56
		3M	94.4	95.0	0.66
		6M	99.4	100.0	0.41
	30°C 65% RH	3M	95.4	96.0	0.43
		6M	101.9	102.5	0.55
		9M	102.3	102.9	0.59
	25°C 60% RH	3M	100.8	101.4	0.29
		6M	96.4	97.0	0.77
		9M	101.0	101.6	0.45
Example 12B	Initial		100.1	100.0	0.10
	40°C 75% RH	1M	99.3	99.2	0.21
		3M	102.2	102.1	0.22
		6M	97.0	96.9	0.29
	30°C 65% RH	3M	99.4	99.3	0.13
		6M	98.5	98.4	0.24
		9M	97.1	97.0	0.26
		12M	97.4	97.3	0.46
	25°C 60% RH	3M	99.1	99.0	0.11
		6M	102.6	102.5	0.16
		9M	100.7	100.6	0.22
		12M	98.7	98.6	0.31
		18M	99.9	99.8	0.37

	24M	98.7	98.6	0.48
	39M	97.9	97.8	0.59

Example 13

One aspect of this invention was to produce a stable lyophilized product and a solvent system with sufficient bulk solution stability to withstand an aseptic processing and lyophilization process. The lyophilized products we have manufactured in most of these studies were made with 80%TBA/20% to 60%TBA/40% water solvent system and the bulk solution for lyophilization stable for 24 hours with minimal degradation. We have achieved this goal. The second aspect of the invention is to identify an appropriate diluent to reconstitute the lyophile to a concentration of ASA about 20mg/ml to about 100mg/ml. The criteria for the diluent is that the neutralizing agent is acceptable and widely used in the injectable formulations, and the pH of the reconstituted solution should be between pH 5.5 to 7.4 (closer to physiological pH) at the target concentration of 20 to 100mg ASA/ml. Using these boundary conditions, we have screened various organic and inorganic basifying agents in the diluent to reconstitute the ASA lyophile. The reconstitution studies were done by reconstituting a 100mg vial with 5ml of solution containing a buffer or a basifying agent or a combination of both. All tested basifying agents are presented in the Table 11.

Table 11: Reconstitution of ASA lyophile with various basifying agents

Basifying agent	Amount added (mg)	Final pH
Arginine	127.5	6.2
Arginine	90	6.2
Sodium carbonate	38.1	6.2
Sodium bicarbonate	58.65	8.2
Sodium bicarbonate	50.0	6.5
Arginine/NaOH	80.0/5.0	7.0
NaOH	20	6.2
Arginine/NaOH	80.0/4.0	6.5
Arginine/NaOH	80.0/3.0	6.4
Arginine/NaOH	40.0/10.0 ¹	6.1
Arginine/NaOH	80.0/4.0 ¹	6.8
Magnesium Oxide	5.4	6.0
Magnesium Oxide	3	5.8
Calcium hydroxide	5.14	undissolved
Manganese oxide	6.03	5.0

Tris	80	6.4
Lysine	93.0	6.0
Sodium phosphate, dibasic	100.0	6.25
¹ Reconstitution concentration is 40mg/ml		

The basifying agents are not limited to what we have tested. Basic oxides, hydroxides and salts of any inorganic alkaline and alkali metals can be used. Similarly, organic bases with pKa above 8.5 can be used to reconstitute the aspirin lyophile. The quantity of basifying agent required to

5 dissolve all aspirin, and to bring the pH of the solution about 6.0 can be determined by titrating 20mg/ml to 100mg/ml aspirin slurry with a basifying agent.

Example 14

The solubility of ASA is greater than 100mg/ml at pH 5.5 and above. In the next phase of invention, we have determined the amount of base required to obtain different concentrations of

10 ASA solutions. We have conducted the study using different concentrations of sodium phosphate, dibasic, to obtain different concentrations of aspirin up to 100mg/ml. Data are presented in table 12.

Table 12: Titrations of various basifying agents to obtain different concentration of ASA

Diluent/Conc. (mg/ml)	Recon. volume(ml)	Aspirin Conc. (mg/ml)	pH
Na ₂ HPO ₄ /20	5	20	6.25
Na ₂ HPO ₄ /25	4	25	6.21
Na ₂ HPO ₄ /33.3	3	33.3	6.18
Na ₂ HPO ₄ /50	2	50	6.25
Tris/16.0	5	20	5.8
Tris/17.4	4	25	6.23
Tris/34.8	2	50	6.41
Tris/69.6	1	100	5.86

15 It should be noted that the concentration of basifying agent to neutralize ASA solution proportionately increases with increase in the concentration of ASA. Titration data for other amino acids can be obtained similarly.

Example 15

All the reconstituted solutions presented in examples 13 and 14 have shown slight haziness. The presence of haziness is concentration independent. However, when the ASA API constituted under identical conditions, the resulting solution did not show any haziness. Several studies were 5 conducted without any success to identify the origin of the haziness. When the reconstituted solution was filtered through a 0.2μ filter, the haziness disappeared. However, there was no change in the concentration of ASA before and after filtration suggesting that the haziness was intrinsically present in the lyophile. When we reconstituted with a basifying agent containing 0.01% or 0.05% polysorbate 80, the haziness disappeared. The haziness is probably due to the 10 presence of residual TBA in the lyophile. The diluent or the solution for reconstitution will, therefore, contain 0.01% to 0.05% polysorbate 80.

Since the aspirin product will be administered via an IV bolus route, tonicity of the final reconstituted solution is a critical factor to avoid pain at the injection site. Hence, we reconstituted the lyophile containing 500mg per vial with selected diluents to different concentrations and 15 measured their tonicity. The data are presented in Table 13

Table 13: Tonicity values of reconstituted solutions of ASA at different concentrations

Nature of buffer	Reconstitution Volume	ASA Concentration	Osmolality (m.Osm/Kg)	pH
20mg/mL Na ₂ HPO ₄ with 0.05% Tween80	25mL	20mg/mL	481	6.09
50mg/mL Na ₂ HPO ₄ with 0.05% Tween80	10 mL	50mg/mL	1172	6.17
34mg/mL Tris Buffer	10 mL	50mg/mL	540	5.79
34mg/mL Tris Buffer with 0.05% Tween80	10 mL	50mg/mL	549	5.84
17.5mg/mL Tris Buffer with 0.05% Tween80	20 mL	25mg/mL	269	5.97
40mg/mL L-Lysine	20 mL	25mg/mL	380	7.97
40mg/mL of L-Lysine with 0.05% Tween80	20 mL	25mg/mL	388	8.10
12mg/mL Na ₂ HPO ₄ and 27mg/mL of Tris buffer with 0.05% Tween80	10 mL	50mg/mL	717	6.14
30mg/mL of lysine and 7.5mg/mL of Tris buffer	20 mL	25mg/mL	338	7.53

68mg/mL Tris Buffer with 0.05% Tween80	10mL	100mg/mL	1060	6.07
68mg/mL Tris Buffer with 0.05% Tween80 Aspirin API 1g	10mL	100mg/mL	1036	5.89

As shown in the table, the osmolality values are higher for 50mg/ml ASA solutions compared to the 25mg/ml solutions. Phosphate buffer may not be an ideal basifying agent due to the high tonicity of the reconstituted solutions. Based on these data, tris or lysine or combination of tris and lysine could be the ideal basifying agents that can be included in the diluent to reconstitute ASA lyophile.

We have conducted IV irritation studies by injecting ASA solution of different osmolalities (300 to 1300 mOsm/kg) in rabbit ear vein. Surprisingly, no irritation was observed even with solutions of high osmolality of 1300. It is an unexpected discovery or finding.

10

Example 16

The next step of development is to ensure that the selected buffer system not only produces a clear colorless solution but also has adequate solution stability. We have taken 1g strength lyophilized vials and reconstituted the vial with the proper volume of the buffer solution to produce 25, 50 and 100 mg/ml ASA concentration. We have measured the pH and tonicity values of the final reconstituted solutions. Solution stability studies were carried out over a period of 8 hours. The data are presented in Table 14.

Table12: Reconstitution stability of Aspirin (25, 50 &100mg/ml) in selected buffer in system

Batch ID	Buffer Diluent conc.	Recon. volume	Aspirin conc.	Time	Conc. (mg/ml)	% of Initial	Osmolality m.Osm/kg	pH
16A	17.5mg/mL Tris with 0.05% PS80	40mL	25mg/mL	Initial	24.6	100.0	271	6.86
				2hrs	24.1	98.1		
				4hrs	24.0	97.5		
				8hrs	23.1	93.6		
16B	17.5mg/mL Tris and 2mg/ml Na ₂ HPO ₄ with 0.05% PS80	40mL	25mg/mL	Initial	24.2	100.0	300	7.10
				2hrs	23.5	97.4		
				4hrs	23.0	95.4		
				8hrs	22.4	94.1		
16C	34 mg/mL of Tris and 2mg/mL Na ₂ HPO ₄ with 0.05% PS80	20mL	50mg/mL	Initial	45.2	100.0	571	6.66
				2hrs	43.7	96.7		
				4hrs	43.6	94.4		
				8hrs	42.0	92.9		

16D	50 mg/mL Na ₂ HPO ₄ with 0.05% PS80	20mL	50mg/mL	Initial	44.8	100.0	1170	5.95
				2hrs	43.5	96.9		
				4hrs	43.3	96.7		
				8hrs	42.2	94.0		
16E	68mg/mL of Tris with 0.05% PS80	10mL	100mg/m L	Initial	106.9	100.0	1060	5.92
				4hrs	99.6	93.2		
16F	68mg/mL of Tris Buffer	10mL	100mg/m L	Initial	109.3	100.0	1038	5.83

As shown in the table, the tonicity values were higher for higher concentrations of ASA solutions. About 6% potency loss occurred over an 8-hour period for solutions reconstituted to 25 and 50mg/ml concentration. All reconstituted solutions with exception of 16F are clear at the end of 8 hours' storage time. In the case of 16F, the vial was reconstituted with buffer only without polysorbate 80. The solution was hazy and remained hazy at the end of 8 hours.

Example 17

In example 12, we have presented stability data of two batches of lyophile. The unusual stability of these two batches and two other earlier exploratory batches could be due to the formation of a solvate of ASA with TBA or due to the formation of crystalline ASA lyophilizate. All lyophiles have residual TBA in the range of 1000 -3000 ppm. Differential scanning calorimetry (Perkin - Elmer, Model # DSC 4000) analysis of these sample showed a distinct melting endotherm suggesting that the drug may present in the crystalline form. We have conducted lyophilization studies ASA bulk solution at different concentrations of aspirin, i.e., 25mg/ml. 50mg/ml and 100 mg/ml to determine if the concentration of aspirin in the bulk solution would have effect on the stability. All these batches showed excellent chemical stability. No loss in potency was seen in all these batches over a 6-month storage at 40°C. These data suggest that the stability of ASA lyophile is independent of aspirin concentration in the bulk solution. Thermal analysis data presented in Table 15.

Table 15: Thermal data of various batches of ASA lyophile

ID	Solvent system	Aspirin conc.	Onset	Melting Pt	Enthalpy $\Delta_{\text{fus}}H(\text{J/g})$
R11-API	Plain API	-	136.29°C	140.19°C	126.1
R11-52	80%TBA:20%WFI	50mg/mL	132.00°C	136.24°C	139.0

R11-53	80%TBA:20%WFI	50mg/mL	132.63°C	136.83°C	111.0
R11-56	80%TBA:20%WFI	50mg/mL	128.55°C	133.31°C	136.0
R11-57	80%TBA:20%WFI	75mg/mL	134.04°C	136.70°C	161.5
R11-58	80%TBA:20%WFI	100mg/mL	132.13°C	135.95°C	211.1
R11-59	15%Ethanol:85%WFI	6mg/mL	125.54°C	129.59°C	166.0
R11-60	80%Ethanol:20%WFI	50mg/mL	126.47°C	132.35°C	160.0

As shown in the table, melting points and enthalpies of fusion ($\Delta_{\text{fus}}H$) of the lyophilized aspirin made with different concentrations, using either TBA/water or ethanol/water, are different from the API --melting points of lyophile are lower and enthalpies are higher. Enthalpy of the lyophile was increasing with increasing in the concentration of ASA in the bulk solution. Higher enthalpy coupled with lower melting point for the lyophilized ASA suggest that anew crystal form or the crystalline material as API of ASA may have formed during the lyophilization. Further investigation to understand the crystalline nature or crystal habit of the lyophilized aspirin product was carried out.

10 Additionally, we have measured the particle size distribution of the lyophiles and API. The measurement of particle size (Malvern, Master sizer 2000) of all the samples were done by using dry powder volume distribution method. The data are presented in table 14. As shown in the table, the particle size distribution of lyophilized products, made with different concentrations of aspirin in the TBA/water solvent system, is significantly smaller compared to the API used to make these 15 batches. For example, the average particle size of 10% of particle is about 11.4 μm for API while the particle size diameter of lyophilized product made with 100mg/ml aspirin concentration was 1.4 μm ---a 10-fold decrease in the particle diameter. Similar trends were seen for D50%, D90% and D100%. Also, particle size of lyophile decreases with increasing the concentration of aspirin in the bulk solution.

Table 16: Particle size distribution of Aspirin API & lyophile

Aspirin conc.	D10% (μm)	D50% (μm)	D90% (μm)	D100% (μm)
API	11.4	92.9	249.5	431.0
50mg/ml	1.8	4.5	9.1	17.6
75mg/ml	1.8	4.3	8.6	15.6
100mg/ml	1.4	4.0	8.4	14.8

Example 18

Since the thermal data of the lyophilized product were significantly different the API
5 that was used to produce the lyophiles and the presence of a distinct melting
endotherrm suggest that the lyophilization of ASA in TBA/water solvent system might
have produced a crystalline material in the vial. We have submitted lyophilized
samples made with 50 and 100mg/ml aspirin concentration in TBA/water and
50mg/ml aspirin concentration in ethanol/water system for X-ray analysis. X-ray
10 (Burker AXS) diffractograms of these samples are presented in Figures 1a- 1d.
As shown in the figures, the X-ray diffractograms clearly demonstrated that the
lyophilization of ASA in TBA/Water solvent system produced a crystalline material
which is similar to the crystalline nature of the API.

15

Example 19

In example 17, we have evaluated the lyophiles that were prepared at different
concentrations of ASA in 80%TBA/20%water. X-ray analyses data suggested that the
crystalline material was consistently produced during the lyophilization process
regardless of ASA concentration in the bulk solution for lyophilization. X-ray

diffractograms pattern of all these lyophiles are similar. Next part of our invention, we have evaluated the effect of varying concentrations of TBA in the bulk solution for lyophilization at a constant ASA concentration of 100mg/ml during the lyophilization process. We tested the lyophiles made from with neat TBA to 70:30 TBA:Water

5 systems (Examples -19A to 19E below). All the lyophiles are crystalline in nature. The X-ray diffractogram patterns were consistent with what we have observed in the earlier examples. These data suggest that the lyophilization process is rugged and consistently produce the same crystalline form of ASA regardless of concentrations of ASA or TBA in the solvent system used for lyophilization. Our invention not only
10 produced crystalline form during the conventional lyophilization process but also the crystalline lyophilizate thus formed is independent of either ASA concentration or the concentration of TBA in the solvent system used for lyophilization. These findings are quite unique, and to the best of our knowledge it was never observed for any other molecules using TBA as solvent for lyophilization.

15 Solid state stability of these lyophiles were evaluated and the stability data are presented in the Table 16. As shown in the table all lyophiles showed excellent stability as previously observed with the earlier batches.

These lyophiles when reconstituted with the special diluent to 100mg/ml ASA concentration, dissolves slowly. The reconstitution time varies 3 to 5 minutes. During
20 the reconstitution, we did observe that vigorous shaking was required to break the lyophilizate. This was attributed to the wettability of the cake. Hence, we prepared a lyophile (Example-19F) containing 10mg/ml mannitol to improve the porosity of the lyophilizate. Since the aqueous solubility of mannitol is quite high, the mannitol dissolves first during the reconstitution thereby providing channels for the diluent to
25 wet and dissolve ASA. As expected we did improve the reconstitution time from 3 to 5 minutes to about 3 minutes. Presence of mannitol did not adversely affect the stability of ASA.

Table 16: Stability of ASA lyophiles produced with varying concentrations of TBA

Example	Bulk solution Composition	ASA concentration in bulk solution	Storage and time period		Content (mg/vial)	% Salicylic Acid	% of Moisture	TBA Content (ppm)
-19A	Neat TBA	100mg/ml	40°C/75% RH	1M	480.9	0.36	ND	4166
				2M	520.5	0.52	ND	ND
			Initial		501.1	0.30	ND	5640
			40°C/75% RH	2M	526.1	0.56	ND	ND
-19B	TBA:WFI (90:10)	100mg/ml	Initial		473.1	0.36	0.03	7320
			40°C/75% RH	1M	481.5	0.16	0.05	6433
				3M	481.3	0.18	0.07	9401
				6M	491.9	0.23	0.09	ND
-19C	TBA:WFI (75:25)	100mg/ml	Initial		552.7	0.64	0.18	6947
	TBA:WFI (75:25)	100mg/ml	40°C/75% RH	1M	506.2	0.26	ND	4902
				Initial	476.3	0.31	ND	3809
			40°C/75% RH	2M	528.2	0.56	ND	ND
-19D	TBA:WFI (70:30)	100mg/ml	Initial		480.6	0.40	0.08	1607
			40°C/75% RH	1M	502.7	0.17	0.08	1558
				3M	501.2	0.18	0.10	1107
				6M	507.2	0.17	0.11	ND
			Initial		519.4	0.23	0.22	968
-19E	TBA:WFI (70:30)	100mg/ml	40°C/75%RH	1M	448.4	0.25	ND	ND
				2M	483.4	0.25	0.25	ND
				3M	528.7	0.41	0.23	ND
			25°C/60%RH	3M	497.4	0.54	0.22	ND
-19F	Mannitol-10mg/ml TBA:WFI (70:30)	100mg/ml	Initial		535.7	0.26	0.17	217
			40°C/75%RH	1M	497.7	0.28	ND	ND
				2M	497.7	0.28	ND	ND
				3M	528.7	0.47	ND	ND
			25°C/60%RH	3M	540.7	0.65	ND	ND

Example 20

5 One aspect of our discovery was to produce a robust lyophilization process where we can consistently produce crystalline ASA during the lyophilization regardless of concentrations of critical components such as TBA, water and ASA. This aspect of invention had been successfully accomplished. Second critical aspect of inventions is produce a lyophile with less than a minute reconstitution time, when reconstituted with
10 a special diluent to 100mg/ml ASA concentration. Rapid dissolution is very critical to

our invention as the intent of this dosage form is to treat patients with Acute Coronary Syndrome (ACS) who require urgent medical intervention. As mentioned earlier, the lyophilizate produced using 80:20 TBA:Water as bulk solution for lyophilization produced a dense cake. When reconstituted with the special diluent, the cake does not 5 get wet and requires vigorous shaking. The lyophilizate dissolves completely after five minutes of vigorous shaking.

To develop a rapid dissolution lyophilizate, one need to improve the porosity and wettability of the cake. Porosity of the cake can be improved by reducing solid contents per mL of bulk solution for lyophilization. For example, the porosity of the 10 lyophilizate increases if we decrease the solid contents. Therefore, we decreased ASA concentration to 50mg/ml from 100mg/ml in the bulk solution for lyophilization. Incorporation of small amount of surfactant such as polysorbate 80 would improve the 15 wettability of the cake. To determine the effect of a lower concentration ASA and the presence of small amount of surfactant, we prepared bulk solutions containing 80:20 TBA: WFI with 50mg/ml ASA concentration and different levels of polysorbate 80 (-20A to -20D). When reconstituted these lyophiles with the special diluent, we observed that reconstitution times were about 5 minutes for -20A,B&C and the 20 reconstituted solutions are slightly hazy. The reconstituted time for -20D is, however, improved to 3 minutes and the solution is clear. The solid-state stability date of these lyophiles are presented in Table 17. As shown in the table, presence of polysorbate 80 has no effect on the stability of ASA.

Table 17: Stability of ASA lyophiles produced with varying concentration of PS-80

#	Bulk solution Composition	ASA concentration in bulk solution	Storage Temp./Time	Content (mg/vial)	% Salicylic Acid	% of Moisture	TBA Content (ppm)
20A	TBA:WFI(80:20)	50mg/ml	Initial	477.4	0.20	0.36	12534
20B	Tween80-0.1mg/ml		Initial	485.7	0.34	ND	ND

	TBA:WFI (80:20)	50mg/ml	40°C/75%RH	1M	526.1	0.72	ND	ND
20-C	Tween 80 0.5mg/ml TBA:WFI (80:20)	50mg/ml	Initial		570.6	0.56	0.14	2898
			40°C/75% RH	1M	544.9	0.51	0.12	3891
				3M	578.2	0.61	0.10	2459
20D	Tween 80- 1.0mg/ml TBA:WFI(80:20)	50mg/ml	Initial		505.5	0.53	0.31	7149
			40°C/75% RH	1M	516.6	1.11	0.28	4281
				3M	482.9	0.89	0.30	4019
			40°C/75%RH	1M	448.4	0.25	ND	ND
				2M	483.4	0.25	0.25	ND
				3M	528.7	0.41	0.23	ND
			25°C/60%RH	3M	497.4	0.54	0.22	ND

Example 21

Another aspect of invention is to produce the lyophile with low levels of residual TBA and a reconstitution time of less one minute. In example 19 (-19B to -19D), we have
5 observed that the increase in percent of water in the bulk solution for lyophilization decreases the residual TBA content in the lyophile. In example 20 (20A—20D), decrease in concentration of ASA in the bulk solution and incorporation of small amount of polysorbate 80 would reduce the reconstitution time. To further fine tune the lyophilize formulation, we employed 65:35 TBA:Water as bulk solution for
10 lyophilization, ASA at 50mg/ml, polysorbate 80 at 0.1mg/ml to enhance wettability of cake, in the presence of different bulking agents such as sucrose, lactose and mannitol. In all three cases we obtained lyophiles with a porous cake and the reconstitution time was instantaneous---as we are adding the special diluent, the contents of the vial were
15 instantaneously going into solution. We have conducted limited stability on these formulations, and the stability is comparable to earlier batches.

Table 18: Stability of ASA lyophiles produced with different bulking agents

Bulk solution Composition	ASA concentration in bulk solution	Storage Temp./ Time		Content (mg/vial)	% Salicylic Acid	% of Moisture	TBA Content (ppm)
Mannitol-10mg/ml Tween80-0.1mg/ml TBA:WFI(65:35)	50mg/ml	Initial		493.8	0.40	ND	8034
		40°C/75%RH	1M	546.4	0.67	ND	ND

Sucrose-10mg/ml Tween80-0.1mg/ml TBA:WFI(65:35)	50mg/ml	Initial		479.1	0.37	ND	8308
		40°C/75%RH	1M	545.2	0.61	ND	ND
Lactose monohydrate - 10mg/ml Tween80- 0.1mg/ml TBA:WFI (65:35)	50mg/ml	Initial		483.9	0.37	ND	9240
		40°C/75%RH	1M	511.9	0.68	ND	ND

Example 21

To confirm our findings, we prepared selected batches of ASA and submitted the final lyophilized samples (500mg/vial) to University of Minnesota for 2-D X-ray analysis,
5 DSC and TGA. The submitted batches

Table 19: Batch summary

Batch No	Composition Details	
	ASA concentration	Bulk Solution for Lyophilization
Rho-11	Plain API-	-
Rho11-121	100mg/mL	TBA:WFI(80:20) -Qs
Rho11-125	100mg/mL	TBA:WFI(75:25) -Qs
Rho11-126	100mg/mL	TBA:WFI(65:35) -Qs
Rho11-127	75mg/mL	TBA:WFI(65:35) -Qs
Rho11-134	50mg/mL	TBA:WFI(65:35)-Qs
Rho11-139	50mg/mL	Mannitol-10mg/ml Tween80 - 0.1mg/ml TBA:WFI(65:35)
Rho11-140	50mg/mL	Sucrose-10mg

		Tween80 - 0.1mg
		TBA:WFI(65:35) -Qs

Example 22

In this example, additional testing was done using:

a) 2D X-ray Diffraction (2D XRD)

5 The D8 Discover 2D X-ray microdiffractometer is equipped with a two-dimensional Vantec detector, video camera / laser alignment system, and a Co K_{α} x-ray radiation point source ($\lambda = 1.79 \text{ \AA}$), which is conditioned with a graphite monochromator. It is also equipped with point collimators of varying sizes and an x, y, z sample stage. Powder sample were mounted for reflection mode on sample holder and
10 an 800 μm collimator was used. Measurement frames were scanned at $20/10^{\circ} 2\theta/\omega$ respectively. Area detector images were finally converted to one-dimensional intensity vs. 2θ data sets by using an averaging integration algorithm. The 2 values are with respect to Co K_{α} radiation ($\lambda = 1.79 \text{ \AA}$) and Cu K_{α} radiation ($\lambda = 1.54 \text{ \AA}$).

b) Differential Scanning Calorimetry (DSC)

15 A differential scanning calorimeter (Q2000, TA Instruments, New Castle, DE) equipped with a refrigerated cooling accessory was used. Dry nitrogen gas was purged at 50 mL/min. The instrument was calibrated with indium. The powder samples were weighed and filled in an aluminum pan and sealed hermetically. The samples were cooled from RT to -10 °C, equilibrated for 1 minute, and heated to 160 °C at 10 °C/min.

20 c) Thermogravimetric Analysis (TGA)

A thermogravimetric analyzer (Q50, TA Instruments, New Castle, DE) was used. Dry nitrogen gas was purged at 50 mL/min during the measurement. The powder

samples were filled in the aluminum pan. The samples were heated to 220°C at 10 °C/min.

Results

Thermal analysis

5 The samples revealed pronounced weight loss around the melting temperature. Therefore, aspirin is likely to melt with decomposition. The melting point of aspirin is reported to be 135 °C (pubchem.ncbi.nlm.nih.gov). The enthalpy of melting of aspirin is reported to be in a range of 162-172 J/g (webbook.nist.gov).

Sample	Temperature at which 10% weight loss [°C] was observed (by TGA)	Melting point (Peak temp) [°C] (by DSC)	Enthalpy of fusion [J/g]
Rho_11	160.4	144.0	168.7
Rho_11_121	139.6	139.3	171.4
Rho_11_125	141.0	139.2	174.3
Rho_11_126	144.9	140.2	172.5
Rho_11_127	142.0	139.4	176.8
Rho_11_134	142.7	137.3	174.3
Rho_11_139	143.5	139.7	154.8
Rho_11_140	142.0	136.3	168.7

10 • XRD pattern of the lyophilized samples match with that of aspirin comparable with the reference diffraction patterns in the Powder Diffraction Files of the International Centre for Diffraction Data (ICDD).

15 1. Aspirin melting point is approximately 135 °C and all the lyophilized samples show melting in the range of 136-140 °C. Rho_11 shows a slightly higher melting temperature (144 °C).

2. Even though the melting enthalpy of lyophilized systems match with literature, enthalpy of melting is not a reliable parameter. 10% weight of loss (obtained

from TGA) is observed at the melting point (obtained from DSC). There may be decomposition at the melting temperature.

3. The lyophilized systems show batch to batch consistency.
4. All the systems show crystalline behavior. See Figure 2

5

What we claim:

1. A liquid aspirin-containing composition having extended stability, comprising:
5 aspirin and a cosolvent containing an organic solvent and water, the ratio of said organic solvent to said water being from about 95/5 to 50/50.
2. The liquid aspirin-containing composition of claim 1, wherein the organic solvent is an alcohol.
- 10 3. The liquid aspirin-containing composition of claim 2, wherein the alcohol is selected from the group consisting of t-butyl alcohol (TBA), n-butanol, ethanol and mixtures thereof.
- 15 4. The liquid aspirin-containing composition of claim 3, wherein the alcohol is t-butyl alcohol.
5. The liquid aspirin-containing composition of claim 1, wherein the ratio of the alcohol to the water is from about 60:40 to about 80:20, preferably from about 65:35 to about 75:25.
20
6. The liquid aspirin-containing composition of claim 1, wherein concentration of the aspirin in the composition is from about 25mg/ml to about 115mg/ml, preferably from about 45 mg/ml to about 75 mg/ml or about 50 mg/ml.
25
7. The liquid aspirin-containing composition of claim 1, further comprising a surfactant, preferably in an amount of from about 0.05 to about 0.5 mg/ml.
8. The liquid aspirin-containing composition of claim 7, wherein the surfactant is
30 polysorbate 80 or Tween 80.
9. The liquid aspirin-containing composition of claim 1, further comprising a dissolution enhancer, preferably in an amount of from about 2 to about 30 mg/ml, preferably from about 5 to about 20 mg/ml.
35

10. The liquid aspirin-containing composition of claim 9, wherein the dissolution enhancer is sucrose or a sugar alcohol, preferably mannitol.
11. The liquid aspirin-containing composition of claim 1, further comprising a buffer, 5 preferably selected from the group consisting of TRIS, glycine or other amino bases with pKa greater than 8.
12. The liquid aspirin-containing composition of claim 1, wherein the amount of aspirin degradation to salicylic acid after 24 hours at ambient temperature is \leq 10 about 2%, preferably \leq about 1.5%, or \leq about 1. 0.
13. A liquid aspirin-containing composition of claim 1, wherein the cosolvent is a mixture of comprising TBA and water, in a ratio of from about 65:35 to about 15 75:25, the aspirin is present in an amount of from about 45 to about 75 mg/ml, and further comprising from about 0.05 to about 0.5mg/ml polysorbate 80 and from about 5 to about 25 mg/ml mannitol.
14. The liquid aspirin-containing composition of claim 1, wherein the cosolvent containing an organic solvent and water is selected from the group consisting of 20 TBA/water, n-butanol water, ethanol/water, PEG-ethanol/water, DMSO/water, DMF/water and PEG/n-butanol/water.
15. The use of the liquid aspirin-containing composition of claim 1 as a bulk solution for preparing lyophilized aspirin. 25
16. A method of preparing lyophilized aspirin, comprising, providing the liquid aspirin-containing composition of claim 1, lyophilizing said composition and recovering the resultant lyophilized aspirin.
17. The method of claim 16, wherein liquid aspirin containing composition contains 30 from about 20 to about 100 mg/ml of aspirin and the cosolvent includes t-butyl alcohol and water, the ratio of t-butyl alcohol to water being from about 80:20 to about 60:40, preferably about 65:35.
18. The method of claim 16, wherein the lyophilized aspirin is crystalline. 35

19. The method of claim 18, wherein the crystalline aspirin has a melting point as determined by differential scanning calorimeter or DSC is in the range of 136 °C to 144 °C.

5

20. Lyophilized aspirin prepared by the method of claim 16.

21. The lyophilized aspirin of claim 20, having shelf life of at least 2 years under ambient storage conditions.

10

22. The lyophilized aspirin of claim 20, comprising less than about 2.0 % total degradation products after 2 years at 25 °C, preferably, less than about 1.5 % or 1.0% salicylic acid by weight after 2 years at 25 °C.

15

23. The lyophilized aspirin of claim 20, wherein the amount of residual t-butyl alcohol in said lyophilized aspirin is less than about 0.5%, preferably from about 500 to about 10,000 ppm or from about 1,000 to about 3,000 ppm.

20

24. The lyophilized aspirin prepared of claim 20, wherein the aspirin is lyophilized from a bulk solution having a concentration of about 50, 75 or 100 mg/ml and said lyophilized aspirin made with the respective concentration has the particle size distribution:

Aspirin conc.	D (0.1) µm	D (0.5) µm	D (0.9) µm	D (1.0) µm
50mg/ml	1.8	4.5	9.1	17.6
75mg/ml	1.8	4.3	8.6	15.6
100mg/ml	1.4	4.0	8.4	14.8

25

25. A kit for aspirin therapy comprising a first container comprising a therapeutic amount of lyophilized aspirin and a second container comprising water, and a basifying agent.

30

26. The kit of claim 25, wherein the second container further comprises a surfactant, preferably in a concentration of from about 0.01 to about 0.4 mg/ml, preferably about 0.2 mg/ml.

27. The kit of claim 25, wherein the surfactant is polysorbate 80.
28. The kit of claim 25, wherein the basifying agent is selected from the group consisting of amino acids, organic bases and inorganic bases or basic salts of alkaline and alkali metals.
5
29. The kit of claim 28, wherein the amino acid or organic base has a pKa is 8.5 or greater.
10
30. The kit of claim 28, wherein the amino acid is selected from the group consisting of arginine, lysine and glycine.
31. The kit of claim 28, wherein the organic base is Tris.
15
32. The kit of claim 28, wherein the inorganic bases or salt forms are selected from the group consisting of sodium carbonate, sodium bicarbonate and sodium phosphate, dibasic.
- 20 33. The kit of claim 25, wherein the amount of basifying agent is an amount sufficient to provide the solution resulting from combining the contents of the first and second containers with a pH of at least about 5.5, preferably about 6.0, more preferably from about 6.0 to about 7.4 or about or near physiological pH.
- 25 34. An intravenously-injectable liquid aspirin-containing composition prepared by combining the contents of the first and second containers in the kit of claim 25.
- 30 35. The intravenously-injectable liquid aspirin containing composition of claim 34, wherein said composition has a tonicity of from about 270 to about 1300 mOsm/kg.
35
36. The intravenously injectable liquid aspirin containing composition of claim 34, comprising from about 20 to about 140 mg/ml, preferably about 100 mg/ml of aspirin, a sugar alcohol, preferably mannitol and a surfactant, said composition having less than about 0.1% TBA therein.

37. A method of providing aspirin therapy, comprising: intravenously administering an effective amount of the liquid intravenously-injectable aspirin-containing composition of claim 34 to a mammal in need thereof.

5 38. The method of claim 37, wherein the amount of aspirin administered intravenously is from about 80 to about 1200 mg, preferably from about 300 to about 1000 mg.

39. The method of claim 37, wherein the aspirin concentration of the composition intravenously administered is from about 20 to about 50 mg/ml.

10

40. The method of claim 37, wherein the volume of the intravenously-injectable aspirin-containing composition administered is from about 1ml to about 10 ml.

15

41. The method of claim 37, wherein the intravenously-injectable aspirin-containing composition is intravenously administered over a period of about 90 seconds or less and preferably over a period of about 60 seconds.

42. The method of claim 37, wherein the mammal is a human.

20

1/5





FIG. 1 a

2/5



3/5




FIG. 1c

4/5




FIG. 1d

5/5




FIG. 2